Eagle Pharmaceuticals, Inc. (EGRX) Income Statement
EGRX 2022 at a glance
Fiscal year ended December 31, 2022 · U.S. dollarsEGRX revenue and net income
Where EGRX's revenue goes
2022Each bar shows an amount and its share of revenue. EGRX kept 11.3% of revenue as net income.
EGRX profit margins
EGRX growth rates
to 2022| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +84.6% | +17.4% | +6.0% | +62.0% |
| Gross profit | +71.4% | +18.0% | +4.3% | — |
| Operating income | +2,823.8% | +54.8% | +1.8% | — |
| Net income | — | +35.5% | −7.3% | — |
| EPS (diluted) | +203.1% | +44.5% | +14.8% | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
EGRX quarterly EPS vs estimates
Eagle Pharmaceuticals beat the analyst EPS estimate in 5 of the last 8 quarters.
EGRX income statement
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $316.6M | $171.5M | $187.8M | $195.9M | $213.3M | $236.7M | $189.5M | $66.2M | $19.1M | $13.7M |
| Cost of revenue | $94.9M | $42.2M | $45.5M | $60.9M | $61.9M | $57.2M | $55.3M | $15.6M | $11.7M | $7.4M |
| Gross profit | $221.7M | $129.4M | $142.3M | $135.0M | $151.4M | $179.5M | $134.2M | $50.6M | $7.4M | $6.3M |
| Research & development | $34.1M | $51.3M | $30.8M | $36.8M | $44.4M | $32.6M | $30.3M | $27.9M | $16.8M | $9.8M |
| Sales, general & admin | $106.6M | $75.3M | $78.6M | $76.4M | $60.5M | $73.1M | $52.3M | $20.2M | $9.3M | $14.8M |
| Total operating expenses | $140.7M | $126.6M | $109.4M | $113.2M | $104.9M | $104.0M | $82.6M | $48.0M | $26.1M | $14.8M |
| Operating income | $81.0M | $2.8M | $33.0M | $21.8M | $36.6M | $74.0M | $53.4M | $2.6M | −$18.8M | −$8.5M |
| Interest income | $271,000 | $560,000 | $562,000 | $2.2M | $158,000 | $91,000 | $84,000 | $14,000 | — | — |
| Interest expense | $4.0M | $1.6M | $2.6M | $2.7M | $2.7M | $1.1M | $8,000 | $11,000 | $8,000 | $1.4M |
| Income before taxes | $61.4M | −$4.5M | $22.7M | $22.0M | $34.0M | $72.9M | $53.4M | $2.6M | −$19.3M | −$6.9M |
| Income taxes | $25.8M | $4.1M | $10.7M | $7.7M | $2.1M | $21.0M | −$28.0M | $3,000 | −$1.3M | −$898,703 |
| Net income | $35.6M | −$8.6M | $12.0M | $14.3M | $31.9M | $51.9M | $81.5M | $2.6M | −$18.0M | −$6.0M |
| EBITDA | $77.5M | $847,000 | $30.0M | $29.3M | $40.4M | $77.8M | $55.0M | $2.7M | −$18.8M | −$8.4M |
| EPS (diluted) | $7.82 | $2.58 | $3.54 | $2.59 | $3.86 | $3.92 | $4.88 | $0.20 | −$1.28 | −$0.43 |
| Gross margin | 70.0% | 75.4% | 75.8% | 68.9% | 71.0% | 75.8% | 70.8% | 76.4% | 38.7% | 46.0% |
| Operating margin | 25.6% | 1.6% | 17.5% | 11.1% | 17.2% | 31.3% | 28.2% | 3.9% | −98.2% | −61.8% |
| Net margin | 11.3% | −5.0% | 6.4% | 7.3% | 15.0% | 21.9% | 43.0% | 3.9% | −94.1% | −44.2% |
| Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | Dec '21 | Sep '21 | Jun '21 | Mar '21 | Dec '20 | Sep '20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $64.6M | $66.3M | $60.7M | $65.9M | $74.1M | $115.9M | $42.3M | $39.9M | $48.1M | $41.2M | $49.9M | $49.9M |
| Cost of revenue | $16.9M | $17.3M | $19.9M | $23.7M | $23.7M | $27.8M | $12.3M | $8.3M | $10.8M | $10.9M | $12.5M | $12.0M |
| Gross profit | $47.8M | $49.0M | $40.8M | $42.2M | $50.5M | $88.1M | $30.0M | $31.6M | $37.4M | $30.4M | $37.4M | $37.9M |
| Research & development | $9.8M | $9.3M | $7.2M | $9.3M | $11.4M | $6.1M | $3.8M | $23.3M | $9.9M | $14.3M | $9.4M | $4.8M |
| Sales, general & admin | $27.7M | $28.0M | $24.1M | $23.5M | $36.8M | $22.2M | $20.3M | $18.5M | $16.6M | $19.9M | $18.2M | $17.7M |
| Total operating expenses | $37.5M | $37.2M | $31.4M | $32.8M | $48.3M | $28.3M | $24.1M | $41.8M | $26.5M | $34.2M | $27.6M | $22.5M |
| Operating income | $10.3M | $6.2M | $9.5M | −$2.3M | $2.2M | $59.8M | $5.9M | −$10.2M | $10.8M | −$3.8M | $9.8M | $15.4M |
| Interest income | $195,000 | $212,000 | $317,000 | — | $244,000 | $154,000 | $165,000 | $197,000 | $163,000 | $35,000 | $20,000 | $46,000 |
| Interest expense | $1.4M | $1.5M | $2.0M | $1.6M | $552,000 | $366,000 | $395,000 | $396,000 | $422,000 | $422,000 | $413,000 | $489,000 |
| Income before taxes | $9.3M | $10.2M | $13.3M | −$45,000 | −$5.9M | $57.7M | $1.2M | −$12.7M | $5.5M | $1.3M | $11.4M | $8.9M |
| Income taxes | $4.1M | $4.5M | $5.1M | $3.5M | $3.6M | $13.6M | $7.4M | −$7.0M | $1.9M | $1.8M | $3.3M | $1.9M |
| Net income | $5.2M | $5.8M | $8.2M | −$3.5M | −$9.4M | $44.1M | −$6.2M | −$5.6M | $3.6M | −$421,000 | $8.1M | $7.1M |
| EBITDA | $16.3M | $17.3M | $20.9M | $1.8M | −$3.7M | $58.9M | $2.7M | −$11.4M | $6.9M | $2.7M | $12.9M | $10.8M |
| EPS (diluted) | $1.18 | $1.26 | $1.10 | $1.12 | $1.56 | $4.04 | $0.85 | $0.56 | $0.93 | — | — | — |
| Gross margin | 73.9% | 73.9% | 67.3% | 64.1% | 68.1% | 76.0% | 70.9% | 79.3% | 77.6% | 73.7% | 74.9% | 76.0% |
| Operating margin | 15.9% | 9.3% | 15.6% | −3.5% | 3.0% | 51.6% | 13.9% | −25.5% | 22.5% | −9.1% | 19.6% | 30.9% |
| Net margin | 8.0% | 8.7% | 13.5% | −5.3% | −12.7% | 38.0% | −14.6% | −14.1% | 7.5% | −1.0% | 16.1% | 14.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in EGRX's financial statements (latest annual report filed March 23, 2023); data from EODHD. Sales, general & administrative expenses include sales and marketing.
EGRX financial results
In fiscal year 2022 (ended December 31, 2022), Eagle Pharmaceuticals reported revenue of $316.6 million, up 84.6% from the year before. It had net income of $35.6 million, a net profit margin of 11.3%. Diluted earnings per share came to $7.82. Over five years revenue grew at an average rate of 6.0% a year.
See the EGRX stock overview for the latest quote and news, or the EGRX chart for price history and technical indicators.
EGRX income statement FAQ
What is Eagle Pharmaceuticals's annual revenue?
Eagle Pharmaceuticals reported total revenue of $316.6 million for fiscal year 2022, which ended on December 31, 2022. That was up 84.6% from $171.5 million the previous year.
Is Eagle Pharmaceuticals profitable?
Yes. Eagle Pharmaceuticals reported net income of $35.6 million in fiscal 2022, a net profit margin of 11.3%; its operating margin was 25.6%.
What is Eagle Pharmaceuticals's gross margin?
Eagle Pharmaceuticals's gross margin was 70.0% in fiscal 2022: for every $100 of revenue, Eagle Pharmaceuticals kept $70 after the direct cost of its products and services.
How much does Eagle Pharmaceuticals spend on research and development?
Eagle Pharmaceuticals spent $34.1 million on research and development in fiscal 2022, 10.8% of revenue.
How fast is Eagle Pharmaceuticals growing?
Revenue grew 6.0% a year on average over the last five fiscal years, from $236.7 million to $316.6 million.
What are Eagle Pharmaceuticals's earnings per share?
Eagle Pharmaceuticals earned $7.82 per diluted share in fiscal 2022, compared with $2.58 a year earlier.
When does Eagle Pharmaceuticals's fiscal year end?
Eagle Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2022 and was filed on March 23, 2023.